Levonorgestrel Patch
AG890
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Transdermal
-
Intended Duration:
- Short-Acting
- Development Stage: Phase II
- Developer(s)/researcher(s): Agile Therapeutics
Details
- API: Levonorgestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Regimen: 1 Patch/Week
- MPT: Not Potential MPT
- Promising Attributes: The patch could be used by individuals with estrogen precluding medical conditions. Patches require less user adherence than a daily-use method.
Product Status
Developer Confirmed Interest in Further Development or Tech Sale
History
2012: Phase I/II trial to evaluate safety and wearability of two LNG-only patches
2021: Agile completes formulation selection and early pre-clinical evaluation of a novel progestin-only contraceptive patch. Development is halted in 2021 to dedicate resources another product in Agile's pipeline, Twirla.
2023: Agile confirms interest in resuming development or licensing AG890 to a new development group.